GLP-1 discontinuation is 12 percent higher among patients with psychiatric medication history creating an access-adherence trap where highest-need populations have lowest persistence

Truveta's analysis of real-world GLP-1 discontinuation patterns found that patients with a history of psychiatric medication use are 12 percent more likely to discontinue GLP-1 therapy compared to those without psychiatric history. This creates a compounding access-adherence trap: patients with co-occurring mental health and metabolic conditions face the highest obesity burden and metabolic disease risk, yet are systematically less likely to both access GLP-1s (due to income and coverage barriers documented in KFF data) AND maintain therapy when they do gain access. The psychiatric comorbidity effect operates independently of income, age, and other comorbidity factors, suggesting a distinct mechanism—potentially related to medication burden, side effect tolerance, or behavioral health system fragmentation. This finding reveals that the population most likely to benefit from GLP-1 therapy (those with multiple chronic conditions including mental health disorders) faces a double barrier: structural access limitations followed by adherence failure even when access is achieved.

Extending Evidence

Source: VigiBase study, Clinical Nutrition 2025

Concurrent prescribing analysis shows OR 4.45 for suicidal ideation reports with antidepressants and OR 4.07 with benzodiazepines. The highest-risk patients are those with pre-existing psychiatric pharmacotherapy, creating a safety-persistence paradox: the patients most likely to discontinue (psychiatric comorbidity) are also those with highest adverse event reporting rates.

Extending Evidence

Source: MDPI Nutrients PMC12694361

Review identifies eating disorder history, perfectionism, OCD traits, and emotion regulation deficits as primary risk factors for GLP-1 adverse psychiatric outcomes. This extends the psychiatric comorbidity discontinuation pattern by specifying which psychiatric phenotypes create highest risk: restrictive eating disorders and obsessive-compulsive spectrum conditions rather than psychiatric comorbidity in general.

Extending Evidence

Source: Lancet Psychiatry 2026, Karolinska Institutet

Swedish study population (95,490 people with pre-existing depression/anxiety) demonstrates that psychiatric comorbidity is both a predictor of GLP-1 prescribing AND a population where the drug shows large protective effects (42% reduction in worsening). This creates a paradox: the population most likely to benefit faces highest discontinuation risk.

Extending Evidence

Source: Sa et al. (2026)

Large observational cohort found 195% increased depression risk and 106% increased suicidal behavior risk in obesity patients, though confounding by indication is suspected. This extends the access-adherence trap by showing psychiatric adverse effects may be concentrated in the population with pre-existing psychiatric comorbidity who already face higher discontinuation rates.